Home › Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars
 

Keywords :   


Premarket Biotech Digest: Exelixis' Milestone, Valeant's Investor Call, Sophiris Soars

2015-11-12 05:49:58| Biotech - Topix.net

Click this link to find out how much you can save.) Exelixis achieved a major milestone on Tuesday as the company's Cotellic was approved by the FDA as a treatment for patients with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf. Cotellic has already been approved in Switzerland earlier this year.

Tags: call investor digest biotech

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.06Tropical Storm Beryl Graphics
29.06Tropical Storm Beryl Forecast Discussion Number 4
29.06Tropical Storm Beryl Wind Speed Probabilities Number 4
29.06Tropical Storm Beryl Public Advisory Number 4
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
29.06Tropical Storm Beryl Forecast Advisory Number 4
29.06Tropical Storm Beryl Public Advisory Number 3A
29.06Summary for Tropical Storm Beryl (AT2/AL022024)
More »